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A B S T R A C T
Background
Intrapartum pharyngeal instillation of surfactant before the first breath may result in surfactant administration to the infant lung,
with the potential benefit of avoiding endotracheal intubation and ventilation, ventilator induced lung injury and bronchopulmonary
dysplasia.
Objectives
To determine the effect of pharyngeal instillation of surfactant before the first breath compared to placebo, no treatment or intratracheal
surfactant administration followed by intermittent positive pressure ventilation (IPPV) on morbidity and mortality in preterm infants
at risk of respiratory distress syndrome (RDS).
Search strategy
Searches were made of CENTRAL (The Cochrane Library, to September 2010), MEDLINE and PREMEDLINE (1950 to September
2010), EMBASE (1980 to 2010) and CINAHL (1982 to 2010). This strategy was supplemented by searches of proceedings of scientific
meetings, Google Scholar and reference lists of identified studies, as well as contact with expert informants and surfactant manufacturers.
Selection criteria
Published, unpublished and ongoing randomised controlled or quasi-randomised trials (using individual or cluster allocation) of
pharyngeal instillation of surfactant before the first breath compared to placebo or no treatment, or intratracheal surfactant instillation
followed by IPPV, on morbidity and mortality in preterm infants at risk of RDS.
Data collection and analysis
Two authors independently assessed study eligibility and quality.
Main results
No published, unpublished or ongoing trials that met the inclusion criteria for this review were found.
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Authors’ conclusions
There were no data from randomised controlled or quasi-randomised trials that evaluated the effect of intrapartum instillation of
pharyngeal surfactant before the first breath. Evidence from animal and observational human studies suggest that pharyngeal instillation
of surfactant before the first breath is potentially safe, feasible and may be effective. Well designed trials are needed.
P L A I N L A N G U A G E S U M M A R Y
Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk
of respiratory distress syndrome
There is no current evidence from clinical trials to guide the use of pharyngeal instillation of surfactant before the first breath in preterm
infants at risk of respiratory distress syndrome.
Respiratory distress syndrome is caused by a deficiency of natural lung detergent (surfactant) and occurs mainly in infants born before
term (37 weeks’ gestation). The usual treatment includes instilling artificial surfactant directly into the newborn infant’s airway followed
by mechanical ventilation. However, this process can lead to lung injury which may affect the infant’s long-term health. A potential
alternative strategy is to instil surfactant into the posterior pharynx as soon as the baby’s head appears, just before delivery of the
shoulders. Thereafter, resuscitation measures are instituted as usual. This procedure has the potential to reduce the need to support the
infant’s breathing after birth, as well as any lung damage caused by mechanical ventilation. We did not find any trials for this review
of pharyngeal instillation of surfactant before the first breath in preterm infants at risk of respiratory distress syndrome. In view of the
encouraging results from animal studies and preliminary human studies, trials of pharyngeal instillation of surfactant before the first
breath in preterm infants at risk of respiratory distress syndrome are needed.
B A C K G R O U N D
Description of the condition
Respiratory distress syndrome (RDS) results from a deficiency of
pulmonary surfactant and is a significant cause of morbidity and
mortality in preterm infants. Randomised controlled trials and
meta-analyses have demonstrated the efficacy of surfactant ther-
apy in both the prevention and treatment of infants with, or at
risk of, RDS. Studies have compared a wide variety of surfactant
preparations. These include synthetic surfactants (Soll 1998a; Soll
1998b) and surfactants derived from animal sources (natural sur-
factants) (Seger 2009; Soll 2002). Although both synthetic and an-
imal-derived surfactant preparations are effective (Soll 1998a; Soll
1998b; Soll 2002; Seger 2009), clinical trials suggest that animal-
derived surfactant may be more effective (Soll 2001a) than pro-
tein-free synthetic surfactant (Tooley 1987). Furthermore, clinical
trials have shown prophylactic surfactant (Soll 1998b; Soll 2001b;
Soll 2002) and early surfactant (Soll 1999; Stevens 2007) are su-
perior to selective use of surfactant in preventing morbidity and
mortality in preterm infants. The trials also suggest that a multi-
ple-dose strategy is superior to a single-dose strategy (Soll 2009).
Tests also point to the successful use of new protein-containing
synthetic surfactants (Pfister 2007) although these preparations
are not currently available for clinical use.
Despite the benefits of surfactant, many infants develop bron-
chopulmonary dysplasia (BPD) and chronic lung disease (CLD).
Although the aetiology of CLD in preterm infants is multifactorial
(Allen 2003), ventilator-induced lung injury (VILI) remains one
of the main implicated risk factors (Coalson 1999; Clark 2000).
We know that only a few resuscitative positive pressure ventilation
(PPV) breaths may result in VILI (Grossmann 1986; Björklund
1997; Fleckonoe 2008; O’Reilly 2008).
Both surfactant prophylaxis and therapy necessitate endotracheal
intubation to facilitate surfactant administration. Although sur-
factant by itself is an established, effective intervention for either
the prevention or treatment of RDS (Soll 1998a; Soll 1998b; Soll
1999; Soll 2001a; Soll 2001b; Soll 2002; Stevens 2007; Seger
2009; Soll 2009), endotracheal intubation and the subsequent use
of PPV are not without side effects.
Endotracheal intubation is a potentially traumatic procedure that
is often performed without optimal pain management (Sarkar
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2006). It may be accompanied by significant haemodynamic in-
stability including hypoxia, bradycardia, blood pressure fluctua-
tion and an intracranial pressure increase (Marshall 1984; Ghanta
2007). Intubation is inevitably associated with colonisation of the
trachea, retained secretions resulting in collapse, differential aer-
ation and high resistance to air flow, resulting in increased work
of breathing and potentially leading to nosocomial pneumonia
and sepsis (Young 2005; Aly 2008). Intubation is associated with
an inflammatory process which can lead to lung injury and BPD
(Young 2005). Current evidence suggests PPV of immature, sur-
factant-deficient lungs is harmful and may exacerbate the devel-
opment of BPD (Björklund 1997; Van Marter 2000). Björklund
reported that resuscitation of surfactant-deficient immature lambs
with as few as six breaths damages the lungs and blunts the ther-
apeutic effect of subsequent surfactant replacement (Björklund
1997). Grossmann 1986 reported similar results. Fleckonoe 2008
reported that just six hours of ventilation were enough to cause
marked airway epithelial injury in very preterm and near-term fe-
tal sheep. O’Reilly 2008 reported that ventilator-induced injury
extends to involving the conducting airways as well.
One approach to surfactant administration is the InSurE (INtu-
bation-SURfactant-Extubation) technique pioneered by Victorin
(Victorin 1990) and Verder (Verder 1994). A review of trials found
that early surfactant replacement therapy with prompt extubation
to nasal continuous positive airway pressure (nCPAP), as in the
InSurE technique, is associated with less need for mechanical ven-
tilation, lower incidence of BPD and fewer air leak syndromes
when compared with later, selective surfactant replacement and
continued mechanical ventilation with extubation from low venti-
lator support (Stevens 2007). However, the limited data available
show the InSurE procedure to be associated with a propensity for
decreased cerebral oxygenation, higher cerebral oxygen extraction
and decreased electric brain activity (Hellström-Westas 1992; van
de Berg 2000). Furthermore, the InSurE procedure may need to
be repeated if the first dose of surfactant was not sufficiently effec-
tive (Bohlin 2007), leading to additional risk of brain damage.
The main strategy used to avoid endotracheal intubation and PPV
in premature infants is application of nCPAP or continuous dis-
tending pressure (CDP) immediately following birth (Kamper
1999; Ho 2002a; Ho 2002b). Recent studies suggest CDP may
lead to less CLD compared to elective intubation, surfactant and
PPV (Aly 2001; de Klerk 2001). Similarly, nasal intermittent pos-
itive pressure ventilation (NIPPV) has shown a decreased need
for intubation and mechanical ventilation. It also reduces the fre-
quency of apnoea and the incidence of CLD without an increase
in adverse effects (Davis 2001; Lemyre 2002). Although CDP and
NIPPV strategies avoid endotracheal intubation and PPV they
preclude surfactant administration, which is a standard and proven
treatment for RDS. Furthermore, CDP, NIPPV and InSurE may
fail in 25% to 50% of preterm infants (Reininger 2005; Kugelman
2007; Morley 2008).
Description of the intervention
Non-invasive methods of surfactant administration have the po-
tential to reduce the need for intubation and endotracheal surfac-
tant administration. Potential strategies include:
1. intra-amniotic instillation (Petrikovsky 1995);
2. pharyngeal instillation (Kattwinkel 2002; Kattwinkel
2004);
3. administration of airway surfactant via a laryngeal mask
(Trevisanuto 2005);
4. administration via a thin endotracheal catheter without
IPPV (Kribs 2007; Dargaville 2010; Kribs 2010);
5. nebulised surfactant administration in spontaneously
breathing infants (Jorch 1997).
This review focuses on pharyngeal instillation of surfactant. The
typical protocol for pharyngeal instillation of surfactant is as fol-
lows (Kattwinkel 2002; Kattwinkel 2004): as soon as the baby’s
head appears on the perineum or at the operative incision, the
mother is instructed to stop pushing and the pharynx and stom-
ach are suctioned with a catheter. A surfactant solution is then in-
stilled into the posterior pharynx through a catheter without direct
laryngoscopy. The baby is stimulated to breathe spontaneously as
soon as the shoulders and rest of the body are delivered. Thereafter,
resuscitation measures are instituted as usual.
How the intervention might work
Pharyngeal instillation of surfactant is designed to administer sur-
factant to the surfactant-deficient lungs by taking advantage of the
normal physiology of establishing breathing air. While the chest
remains compressed in the birth canal, fetal lung fluid is suctioned
from the future upper airway and is replaced with a surfactant-con-
taining solution. The chest expands as it is released into the vaginal
vault and beyond and the baby is stimulated to aspirate the sur-
factant-containing solution, providing surfactant at the advancing
air-fluid interface. The technique is designed to avoid endotra-
cheal intubation whilst offering the benefits of surfactant admin-
istration. Combining pharyngeal surfactant administration with
prenatal steroid administration and CDP offers potential synergy
to treat RDS, avoiding both endotracheal intubation and PPV,
thereby reducing lung injury that may lead to BPD.
Animal studies in rabbits and lambs indicate that surfactant de-
position into the posterior pharynx before the first breath per-
mits aspiration of surfactant at initiation of ventilation, improves
expansion of the lungs and prolongs survival (Enhorning 1973;
Cummings 1995). Furthermore, animal studies have shown that
surfactant is more uniformly distributed (Jobe 1984) and pul-
monary function maintained for a longer time (Cummings 1995)
if surfactant is delivered to fluid-filled rather than air-filled lungs.
Why it is important to do this review
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Despite significant advances in neonatal intensive care, CLD re-
sults in a significant health burden to preterm infants born at
less than 32 weeks’ gestation who received mechanical ventila-
tion. CLD results in substantial neonatal and infant morbidities
and health resource utilisation (Allen 2003). It is associated with
chronic respiratory difficulties (Kilbride 2003; Doyle 2006); pro-
longed and recurrent hospitalisation (Chye 1995); neurodevelop-
mental disabilities including cerebral palsy, neurosensory and mo-
tor disabilities (Skidmore 1990; Singer 1997; Majnemer 2000)
and poor cognitive outcome (Hughes 1999). CLD has a major
impact on the daily lives of families, which persists beyond the
neonatal period (Korhonen 1999). Pharyngeal instillation of sur-
factant before the first breath is a physiologic and logical technique
with the potential benefit of avoiding ventilation, VILI and pos-
sibly BPD.
O B J E C T I V E S
To determine the effect of pharyngeal instillation of surfactant be-
fore the first breath compared to placebo, no treatment or intra-
tracheal surfactant administration followed by intermittent pos-
itive pressure ventilation (IPPV) on morbidity and mortality in
preterm infants at risk of RDS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials using randomisation or quasi-randomisation of patients re-
gardless of the unit of allocation (individual or cluster) were eligi-
ble for inclusion. Published or unpublished and ongoing studies
were eligible for inclusion.
Types of participants
Participants were mother-infant dyads. We included preterm in-
fants of less than 32 completed weeks’ gestation that were at risk of
RDS. Infants should have had the intervention attempted before
the first breath to be eligible.
Types of interventions
Pharyngeal instillation of surfactant, attempted before the first
breath at any dose and using any type of surfactant (synthetic,
animal-derived or protein-containing synthetic), compared with
placebo, no treatment or intratracheal instilled surfactant. We
planned to perform separate comparisons for all the above groups.
Types of outcome measures
Primary outcomes
Primary outcome measures included:
1. chronic lung disease (CLD), defined as need for oxygen or
respiratory support at 36 weeks postmenstrual age (PMA);
2. mortality prior to hospital discharge;
3. neurodevelopmental disability at a minimum of 18 months
postnatal age, defined as neurological abnormality including
cerebral palsy on clinical examination, developmental delay of
more than two standard deviations below the population mean
on a standardized test of development, blindness (visual acuity
less than 6/60) or deafness (any hearing impairment requiring
amplification) at any time after the age was term corrected.
Secondary outcomes
Secondary outcome measures included other measures of effec-
tiveness, complications, satisfaction with care and health service
use for both women and infants. These included any of the fol-
lowing.
A. Infants
1. Fetal trauma during intervention
2. Bradycardia during intervention
3. Discontinuation of intervention because of fetal side effects
(e.g. bradycardia)
4. Apgar score less than 7 at five minutes
5. Metabolic acidaemia (pH less than 7.05 or base deficit
greater than12 mmol/L, or both) in cord artery blood
6. Perinatal asphyxia (Stage 1 to 3: Sarnat and Sarnat Stages of
Hypoxic-Ischaemic Encephalopathy)
7. Need for positive pressure ventilation via neopuff or bag
and mask during resuscitation at delivery
8. Need for intubation during resuscitation at delivery
9. Need for chest compression during resuscitation at delivery
10. Need for adrenaline during resuscitation at delivery
11. Intratracheal surfactant received post-intervention
12. Doses of post-intervention surfactant
13. Hypothermia post resuscitation (a core body temperature of
less than 36.5 °C or a skin temperature of less than 36 °C)
14. Respiratory distress syndrome (however defined by authors)
15. Need for mechanical ventilation
16. Days of mechanical ventilation
17. Days of continuous positive airway pressure (CPAP)
18. Days of high-flow nasal cannula
19. Days of low-flow nasal cannula
20. Use of high-frequency oscillatory ventilation (HFOV) as a
rescue treatment for respiratory distress
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21. Use of jet ventilation as a rescue treatment for respiratory
distress
22. Use of extracorporeal membrane oxygenation (ECMO) as a
rescue treatment for respiratory distress
23. Use of postnatal corticosteroids as rescue treatment for
respiratory distress
24. Days of supplemental oxygen
25. Incidence of pulmonary interstitial emphysema
26. Incidence of pneumothorax
27. Chronic lung disease (CLD) defined as need for oxygen at
28 days of age
28. Use of diuretic as prophylaxis or rescue treatment for CLD
29. Use of postnatal corticosteroid as prophylaxis or rescue
treatment for CLD
30. Use of home oxygen
31. Apnoea treated with methylxanthines or CPAP
32. Hypotension (however defined by authors) requiring
inotropic support
33. Systemic infection - early (first 48 hours of life) and late
34. Intraventricular haemorrhage (any and severe: Papile grade
equal to or greater than 3)
35. Periventricular leukomalacia (however defined by authors)
36. Symptomatic patent ductus arteriosus, or treated with
cyclo-oxygenase inhibitors or surgical ligation
37. Proven necrotising enterocolitis (Bell stage equal to or
greater than 2)
38. Retinopathy of prematurity (any and severe: stage equal to
or greater than 3)
39. Neonatal mortality (less than 28 days of age)
40. Days to regain birthweight
41. Postnatal growth failure (e.g. weight at discharge less than
10th percentile)
42. Duration of hospitalisation (days)
43. Asthma diagnosed by physician or challenge test
44. Rehospitalization for asthma
45. Rehospitalization for hyperactive airway disease
46. Rehospitalization for pneumonia
B. Mother
1. Discontinuation of intervention because of maternal side
effect or discomfort
2. Maternal satisfaction or stress as measured on validated scale
3. Postpartum haemorrhage (clinically estimated blood loss
greater than or equal to 500 ml at time of birth and up to 24
hours)
4. Interval from pharyngeal surfactant instillation to delivery
5. Length of maternal hospitalisation (days)
Search methods for identification of studies
See: Cochrane Handbook for Systematic Reviews of Interventions
Handbook (Cochrane Handbook 2008) for methods used in re-
views.
We used the standard search strategy of the Cochrane Neona-
tal Review Group as outlined in The Cochrane Library. We con-
sidered unpublished studies as eligible for review. The search of
MEDLINE and PREMEDLINE (via the Ovid interface) included
the following MeSH terms and text words: “infant, premature,
preterm, newborn, neonate”, “surfactant”, “laryngeal“, ”mask“,
”airway“. We limited our searches to “randomized and quasi-ran-
domised clinical trials”. We did not apply language restrictions.
The search strategy for MEDLINE and PREMEDLINE was as
follows.
#1 exp pregnancy
#2 exp infant premature
#3 exp infant newborn
#4 exp obstetric labor premature
#5 exp premature birth
#6 pregnan*.mp OR prematur*.mp OR preterm.mp OR
neonat*.mp OR infant*.mp OR newborn.mp
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 pharyngeal.mp
#9 oral.mp OR mouth
#10 nasl.mp
#11 oropharynx.mp
#12 nasopharynx.mp
#13 intrapartum.mp
#14 intra-partum.mp
#15 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#16 exp pulmonary surfactants
#17 surfactant*.mp OR Beractant.mp OR Poractant.mp OR
Curosurf.mp OR Survanta.mp OR Exosurf.mp OR Lucinac-
tant.mp
#18 #15 OR #16 OR #17
#19 #7 AND #15 AND #18
We adapted the above search strategy to suit other electronic
sources.
Electronic searches
We adapted the search strategy above to search the following elec-
tronic databases:
1. The Oxford Database of Perinatal Trials;
2. Cochrane Central Register of Controlled Trials (CENTRAL);
3. MEDLINE and PREMEDLINE (1966 to 2010) via OVID
interface;
4. EMBASE (1980 to 2010) via OVID interface;
5. CINAHL (1982 to 2010) via EBSCO interface;
6. Google Scholar.
Searching other resources
We carried out additional searches as follows.
1. Ongoing trials in the following trial registries (searched October
2010):
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• ClinicalTrials.gov (U.S. National Institutes of Health),
• Current Controlled Trials,
• Australian New Zealand Clinical Trials Registry,
• International Clinical Trials Registry Platform (ICTRP).
2. Abstracts of conferences from:
• Proceedings of Pediatric Academic Societies (American
Pediatric Society, Society for Pediatric Research and European
Society for Pediatric Research) (from 1990 to 2010) from the
journal ”Pediatric Research“ and abstracts online;
• Proceedings of European Academy of Paediatric Societies
(EAPS), The European Society for Paediatric Research (ESPR),
European Academy of Paediatrics (EAP) and European Society
of Paediatric and Neonatal Intensive Care (ESPNIC) (2003 to
2009) from abstracts online;
• Proceedings of Perinatal Society of Australia and New
Zealand (PSANZ) (1996 to 2010) handsearched from the
published proceedings.
3. Reference lists. After reading the identified individual studies
that examined the effect of pharyngeal surfactant installation on
morbidity and mortality in preterm infants at risk of RDS, we
screened the reference lists of these papers to identify other relevant
studies
4. Personal communications with expert informants and authors
of included studies.
5. Pharmaceutical companies. We contacted the company (Abbott
Laboratories, Inc) that developed different types of surfactant for
possible unpublished studies using their products.
Data collection and analysis
We planned to use the standardized review method of the
Cochrane Neonatal Review Group (CNRG) for conducting a sys-
tematic review (http://neonatal.cochrane.org/en/index.html). We
planned to enter and cross-check data using Review Manager 5
software (RevMan 2008).
Selection of studies
Both review authors independently assessed study eligibility for
inclusion in this review. We retrieved full text versions for poten-
tially eligible studies when the abstract provided inadequate infor-
mation.
Data extraction and management
Both review authors independently extracted data from the full-
text articles using specifically designed spreadsheets to manage
the information. We planned to use these forms to decide on
trial inclusion and exclusion, extract data from eligible trials and
to request additional published information from authors of the
original reports. We planned to compare the extracted data for any
differences. If noted, we planned to resolve differences through
mutual discussion and consensus.
Assessment of risk of bias in included studies
We planned to use the standardized review methods of The
Cochrane Collaboration to assess the methodological quality of
studies (Higgins 2008). The review authors planned to indepen-
dently assess the quality and risk of bias of the potential studies
based on the following six domains:
1) sequence generation;
2) allocation concealment;
3) blinding of participants, personnel and outcome assessors;
4) incomplete outcome data;
5) selective outcome reporting;
6) other sources of bias.
When necessary, we planned to request additional information
and clarification of published data from the authors of individual
trials. We planned to assess each trial for risk of bias based on the
criteria listed above and mark as:
a) low risk of bias;
b) unclear risk of bias;
c) high risk of bias.
We planned to resolve discrepancies by consensus and to report
any persisting discrepancies.
Measures of treatment effect
We planned to report dichotomous data using relative risk (RR)
and risk difference (RD) with 95% confidence intervals (CI). If
there was a statistically significant reduction in RD we planned
to calculate the number needed to treat (NNT) and associated
95% CI. We planned to report mean differences with 95% CI for
continuous outcomes.
Unit of analysis issues
The unit of randomisation is the intended unit of analysis and is
expected to be individual infants.
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
along with individually randomised trials. We planned to analyse
them using the methods described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008) using an
estimate of the intra-cluster correlation coefficient (ICC) derived
from the trial (if possible) or from another source. If we use ICCs
from other sources, we planned to report this and conduct sensi-
tivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we planned to synthesise the relevant information.
We considered it reasonable to combine the results from both if
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there is little heterogeneity between the study designs and inter-
action between the effect of intervention and the choice of ran-
domisation unit is unlikely.
Dealing with missing data
We planned to obtain missing data from the authors, when pos-
sible. If this is not possible, we planned to conduct analyses on
available data (that is ignoring the missing data). In addition, we
planned to conduct another analysis by using imputation meth-
ods (both best and worst scenarios) and last observation carried
forward (LOCF) to the final assessment method for dichotomous
and continuous outcome data, respectively.
For dichotomous outcomes we planned to conduct both best and
worst scenarios and intention-to-treat (ITT) analysis with impu-
tation. We planned to compare results obtained from two analysis
options to arrive at a better understanding of the robustness of
results relative to the different analytic approaches. We planned to
consider an imputation approach of best case scenarios (that is all
missing participants in the intervention group did not experience
a bad outcome such as death or BPD and all missing participants
in the control group experienced a bad outcome) and worst case
scenarios (that is all missing participants in the intervention group
experienced the event and all missing participants in the control
condition did not). We planned to conduct a sensitivity analysis to
compare results based on different imputation assumptions (that
is best versus worst scenarios).
We planned to analyse missing continuous data on an endpoint
basis, including only participants with a final assessment or using
LOCF to the final assessment if the trial authors reported LOCF
data.
Assessment of heterogeneity
We planned to use Review Manager software version 5 (RevMan
2008) provided by The Cochrane Collaboration to assess the het-
erogeneity of treatment effects between trials. We planned to es-
tablish the two formal statistics described below.
1) The Chi2 test to assess whether observed variability in effect sizes
between studies was greater than would be expected by chance.
Since this test has low power when the number of studies included
in the meta-analysis is small, we will set the probability at the 10%
level of significance.
2) The I2 statistic to ensure that pooling of data is valid. We
planned to grade the degree of heterogeneity as: 0% to 30%, might
not be important; 31% to 50%, moderate heterogeneity; 51%
to 75%, substantial heterogeneity; 76% to 100%, considerable
heterogeneity.
Where there is evidence of apparent or statistical heterogeneity, we
planned to assess the source of the heterogeneity using sensitivity
and subgroup analysis looking for evidence of bias or methodolog-
ical differences between trials.
Assessment of reporting biases
We planned to assess reporting and publication bias by examining
the degree of asymmetry of a funnel plot in RevMan 5 (RevMan
2008).
Data synthesis
We planned to perform statistical analyses according to the recom-
mendations of the Cochrane Neonatal Review Group (CNRG)
(http://neonatal.cochrane.org/en/index.html). We planned to
analyse all infants randomised on an intention-to-treat basis. We
planned to analyse treatment effects in the individual trials. In the
first instance we planned to use a fixed-effect model to combine the
data. For any meta-analyses of categorical outcomes we planned to
calculate typical estimates of RR and RD, each with its 95% CI.
For continuous outcomes we planned to calculate the mean differ-
ence (MD) if outcomes were measured in the same way between
trials. We planned to establish the standardized mean difference
(SMD) to combine trials that measured the same outcome but
used different scales. Where we consider meta-analysis to be in-
appropriate, we planned to analyse and interpret individual trials
separately.
Subgroup analysis and investigation of heterogeneity
If sufficient data were available, we planned to explore potential
sources of clinical heterogeneity through the following a priori
subgroup analyses:
1. dose of surfactant (same dose as intratracheal, more than
intratracheal dose);
2. gestational age at delivery (less than 27, 27 to 28, 29 to 32
completed weeks’ gestation);
3. type of surfactant used (synthetic, animal-derived or
protein-containing synthetic).
Sensitivity analysis
If sufficient data were available, we planned to explore method-
ological heterogeneity through the use of sensitivity analyses. We
planned to perform sensitivity analyses by excluding trials of lower
quality, based on a lack of any of the following: allocation conceal-
ment, adequate randomisation, blinding of treatment, less than
10% loss to follow up.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
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Results of the search
The search of the sources above did not find any published, un-
published or ongoing randomised or quasi-randomised controlled
trials to be considered for inclusion in this review.
Excluded studies
One non-randomised study (case series) of pharyngeal instillation
of surfactant (Kattwinkel 2002; Kattwinkel 2004) was excluded.
Risk of bias in included studies
Not applicable, as no eligible studies were found meeting the in-
clusion criteria for this review.
Effects of interventions
There are no trials that meet the inclusion criteria for this review.
D I S C U S S I O N
Pharyngeal instillation of surfactant is designed to administer sur-
factant to the surfactant-deficient lung by taking advantage of the
normal physiology of establishing air breathing. This technique
is potentially useful for administration of prophylactic surfactant.
In a feasibility study, Kattwinkel 2004 studied a non-random pur-
posive sample of 23 preterm newborns. Generally, there was suf-
ficient time (usually approximately 30 to 45 seconds) for the pro-
cedure during vaginal births with vertex presentations, but not
vaginal breech or caesarean section. The study showed that na-
sopharyngeal surfactant instillation at birth appears to be relatively
safe and simple to accomplish, especially for vaginal births. No
major complications from the study procedure were encountered.
However, a large randomised clinical trial (RCT) will be required
to determine the efficacy of this technique. Fernandes 2005 dis-
cussed certain issues that need to be addressed before applying this
technique in randomised trials and clinical practice.
1. Dose of surfactant: it was suggested to use a greater volume
of surfactant for nasopharyngeal administration than is used for
intratracheal instillation as it is unlikely that the entire dose of
surfactant will be aspirated. Alternatively, a more concentrated
surfactant solution for nasopharyngeal instillation could be used.
2. Quantification of the amount of surfactant aspirated: this will
need to be addressed before embarking on a large RCT. Fernandes
2005 suggested using perflurocarbon-surfactant mixture, which
would have the dual advantages of allowing visualization of the
radio-opaque perflurocarbon on chest radiograph as well as at-
tenuation of a pulmonary inflammatory response (von der Hardt
2002; von der Hardt 2004), which might contribute to decreased
incidence of chronic lung disease.
3. Whether extremely preterm infants (especially < 28 weeks ges-
tation) are able to muster sufficient respiratory effort to aspirate
nasopharyngeal surfactant needs further evaluation.
Animal studies in rabbits and lambs indicate that surfactant de-
position into the posterior pharynx before the first breath per-
mits aspiration of surfactant at initiation of ventilation, improves
expansion of the lungs and prolongs survival (Enhorning 1973;
Cummings 1995). Furthermore, animal studies have shown that
surfactant is more uniformly distributed (Jobe 1984) and pul-
monary function maintained for a longer time (Cummings 1995)
if surfactant is delivered to a fluid-filled rather than air-filled lung.
Summary of main results
No eligible trials were identified that assessed the effect of pharyn-
geal instillation of surfactant before the first breath, compared to
placebo, no treatment or intratracheal surfactant instillation with
IPPV, on morbidity and mortality in preterm infants at risk of
RDS.
Overall completeness and applicability of
evidence
Since no eligible trials were identified, there is no evidence from
randomised clinical trials to assess the effectiveness of pharyngeal
surfactant administration in preterm infants.
Quality of the evidence
There are no trials that met the inclusion criteria for this review.
Potential biases in the review process
Searches were made for published and unpublished trials includ-
ing proceeding from scientific meetings, citations of studies and
reviews, expert informants, trial registries and surfactant manu-
facturers. No trials were found that met the inclusion criteria for
this review.
Agreements and disagreements with other
studies or reviews
There are no trials that met the inclusion criteria for this review.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from randomised clinical trials to support or
refute the use of intrapartum instillation of pharyngeal surfactant.
The use of pharyngeal instillation of surfactant should be limited
to randomised controlled trials.
Implications for research
The data available from uncontrolled human and animal studies
have shown a potential benefit of intrapartum pharyngeal instil-
lation of surfactant and justify the conduct of randomised con-
trolled trials. Infants enrolled in such trials should be stratified by
gestation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kattwinkel 2002 Non-randomised study (case series).
Kattwinkel 2004 Non-randomised study (case series).
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D A T A A N D A N A L Y S E S
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